Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis

Rituximab-based chemo-immunotherapy is currently the standard first-line treatment for Waldenstrom macroglobulinaemia (WM), while ibrutinib has emerged as an alternative. In the absence of randomised trials (RCTs) comparing these regimens, the optimal first-line treatment for WM remains uncertain. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Wee-Lee, Chong, Vanessa Cui Lian, Wee, Ian Jun Yan, Poon, Li Mei, Chan, Esther Hian Lee, Lee, Joanne, Chee, Yen-Lin, Jeyasekharan, Anand D., Chng, Wee-Joo, Samuel, Miny, de Mel, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485051/
https://www.ncbi.nlm.nih.gov/pubmed/37679351
http://dx.doi.org/10.1038/s41408-023-00916-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485051/
https://www.ncbi.nlm.nih.gov/pubmed/37679351
http://dx.doi.org/10.1038/s41408-023-00916-5

Ejemplares similares